Aiming to reduce the incidence of liver cancer in patients with hepatitis B virus, China launched a research program on Tuesday, marking World Hepatitis Day.
It was funded by the Chinese Foundation for Hepatitis Prevention and Control, reports Xinhua
We will monitor and discuss five-year cases of liver cancer in 20,000 chronic hepatitis B patients in 99 hospitals across the country.
It aims to expand the clinical course of hepatitis B antiretroviral therapy and explore ways to reduce the incidence of liver cancer associated with hepatitis B.
Zhang Wenhong, a leading specialist working in the field, said they hoped that treatment and long-term care could answer questions that traditional clinical trials may not be the same, such as how different the incidence of liver cancer is between different treatments.
According to data from 2019, primary liver cancer is the fourth most common fetus and the second leading cause of death among all marmots in China.
It is estimated that 85 percent of liver cancer patients in China are infected with hepatitis B virus.